Data Hiperplasia Endometrium dari Histopatolog
KESIMPULAN DAN SARAN
5.1. Kesimpulan
1. Hiperplasia endometrium non atipik simpleks dan kompleks didominasi oleh kelompok usia > 40 tahun
2. Proporsi ekspresi Bcl2 pada hiperplasia endometrium non atipik simpleks dan kompleks lebih banyak dengan intensitas lemah. 3. Rerata intensitas ekspresi imunohistokimia Bcl2 jaringan
hiperplasia endometrium non atipik simpleks sedikit lebih rendah dari hiperplasia endometrium non atipik kompleks. Secara statistik dengan uji Mann-Whitney menunjukkan tidak adanya perbedaan yang bermakna gambaran intensitas ekspresi imunohistokimia Bcl2 jaringan hiperplasia endometrium non atipik simpleks dengan hiperplasia endometrium non atipik kompleks.
5.2. Saran
Perlu dilakukan penelitian lebih lanjut tentang faktor pro apoptosis dan anti apoptosis yang berhubungan dengan hiperplasia endometrium. Perlu adanya standar yang baku dalam pelaporan maupun pencatatan interpretasi hasil pemeriksaan histopatologi.
56 DAFTAR PUSTAKA
1. Palmer J, Perunovic P, Tidy J, Review Endometrial Hyperplasia. The
Obstetrician & Gynaecologist 2008;10:211–216.
2. Reed S.D, Newton K.M. et al. Incidence Of Endometrial Hyperplasia.
Am J Obstet Gynecol. 2009; 200 (6): 678.
3. Montgomery B. Daum G. Dunton C. Endometrial Hyperplasia: A
Review. Obstetrical and Gynecological Survey. 2004: 368-376
4. Trimble C et al. Management of Endometrial Precancers. The
American Collage of Obstetricians and Gynecologist Vol. 120, No.5: 1160-1172
5. Vaskivuo T. Tumor Necrosis Factor-α, and NF-ĸB in Human
Endometrial Hyperplasia and Carcinoma. Obstetric and Gynecology University of Oulu. 2002. 1463-1471
6. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a dominant
regulator of apoptotic cell death. Cell. 1993; 74: 597-608
7. Busmianis I. Ho T, Tan S, Khoo K. P53 and Bcl-2 Expression in
Invasive and Pre-Invasive Uterine Papillary Serous Carcinoma and Atrophic Endometrium. Annual Academy Medicine Singapore. 2005:34:423-424
8. Loffe OB, Papadimetriou JC,et al. Correlation of proliferation
indices,apoptosis, and related oncogene expression (bcl-2 and c-erbB- 2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29(10):1150-9
9. Kokawa K, Yagi S, et al. Apoptosis andthe expression of Bax and Bcl-2
in hyperplasia and adenocarcinoma of the uterine endometrium. Hum Reprod 2001;16:2211-18
10. Gewies A. Introduction to Apoptosis. Aporeview. 2003: 1-26.
11. Bronchud, M.H., 2004. BCL2 in : Principle of Molecular Oncology, 2nd
Ed. Humana Press. p. 82-85.
12. Elmore S, Apoptosis : Riview of programmed cell death. Toxicol Patol,
2007; 2007; 35 (4): 495 – 516
13. Ignae HF, Peter H.K, death and anti death : resistance to apoptosis,
Nature review.2002. Vol 2: 277 – 288
14. Sheau, Y. S and Aaron J.W.H., 2000. Tissue specific bcl-2 protein
partners in apoptosis: An ovarian paradigm. Physiological review vol 80, No 2, pp. 593-610
15. Walensky, L.D., 2008. Multimodal Targeting of the BCL-2 family in
Cancer. American Association for Cancer Research Education Book. http://educationbook.aacrjournals.org
16. Taylor R, Sean P, Seamous J. Apoptosis : Controlloed demolition at
the cellular level. Nature review. 2008. Vol 9.231 – 241
17. Yoshimura S, Banno T et al. Ceramid Formation Leads to Caspase 3
Activation During Hypoxic PC12 Cell Death. Inhibitory Effect of Bcl-2 onCerami Formation and Caspase-3 Activation. J.Biol.Chem.273:6921- 6927
18. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in
cancer therapy. CA Cancer J Clin 2005;55:178-94
19. Chang H.Y and Yang X 2000. Proteases for cell Suicide : Functions
and regulation of caspase. Microbiol. Mol.Biol. Rev.64:821-846
20. Wong R.S Apoptosis in cancer : from pathogenesis to treatment.
Journal of Experimental & Clinical Cancer Research, 2011,30 :87
21. De vita, Rosenberg S. Cancer Principal & Practice of oncology Book
1,7th . Lippincot William and Wilkins,@ 005 : 95 – 102
22. Rautureau, G.J.P., Catherine, L., Mark, G. H,. 2010. Intrinsically
Disordered Proteins in Bcl-2 Regulated Apoptosis. International Journal Molecular Sciences,11 :1808-1824.
23. Kumar, Robbins, Leonard, S., Vinay, 2010. Neoplasia in:
Robbins&Cotran Pathologic Basis of Disease, 8th ed. Philadelphia: Saunders Elsevier: 269-342.
58 24. Daniel N.N, Krosmeyer, S.J 2004. Cell death : Critical control Points
Cell.116 : 205-219
25. Cory, S. and Adams, J.M., 2002. The Bcl2 family: regulators of the
cellular life-or-death switch. Nat Rev Cancer 2, pp. 647.
26. Guset G et al. Bcl-2 Expression in Endometrial Carcinoma in Relation
to Different Histopathologic Prognostic Factors. Journal of Experimental Medical Surgical Research. 2010: 251-254. Bcl 2 inhibit onkogen
27. Krysko D, Berghe T, Herde K, Vandenabeele P. Apoptosis and
Necrosis: Detection, Discrimination and Phagocytosis. 2007. 205-220
28. Karunananda A. Management of Atypical Endometrial Hyperplasia.
European International Journal of Applied Science and Technology. 2014. 1-5.
29. Steinbakk A et al. Molecular Biomarkers in Endometrial Hyperplasias
Predict Cancer Progression. American Journal of Obstetric and Gynecology. 2011:375.e2.
30. Dorjgochoo T et al. Association of Genetic Markers in Bcl-2 Family of
Apoptosis-Related Gees with Endometrial Cancer Risk in a Chinese Population. 2013: 1-2
31. Driak D. Changes in Expression of Some Apoptotic Markers in
Different Types of Human Endometrium. Read periodical. 2011.1.
32. Elmer P. Image-based Quantification of Apoptosis-Driven Nuclear
Fragmentation using the Opera. Perkin Elmer. USA. Jan 2010: 1-3.
33. Aylyyon.V, Cayla.X, et al. Bcl-2 Targets Protein Phosphatase 1α to
Bad. TJOI. 2014: 1-9.
34. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a dominant
regulator of apoptotic cell death. Cell. 1993; 74: 597-608.
35. Sarmadi et al. Immunohistochemical expression of estrogen and
progesterone receptors in endometrial hyperplasia and endometrioid carcinoma. Tehran University Medical Journal. 2012; 70 (3): 156-161.
36. Upson K,Allison K.H, et al. Biomarkers of progestin therapy resistance
and endometrial hyperplasia progression. Am. J. Obstet Gynecol. NIH. 2012; 207 (1): 36-38.
37. Dorjgochoo T,Xiang Y.B,et al. Association of Genetic Markers in the
BCL-2 Family of Apoptosis-Related Genes with Endometrial Cancer Risk in a Chinese Population. PLOS. 2013; 8 (4): 1-9.
38. Cahyanti RD. Bcl-2 dan Indeks Apoptosis pada Hyperplasia
Endometrium Non Atipik Simpleks dan Kompleks. Undip. 2008: 1-88
39. Barhoom S. Sharom A. Bcl-2 proteins link programmed cell death with
growth and morphogenetic adaptations in the fungal plant pathogen Colletotrichum gloeosporioides. Departement of Plant Science. 2006; 22: 32-43.
40. Santoso D. Apoptosis Index Between Females And Males In Reguler
Hemodialysis. Media Clinical Pathology and Medical Laboratory. 2013; 19 (3):P 1-2.
41. Teguh M. Mose J.C,et al. Perbedaan Indeks Apoptosis Plasenta
Antara Preeklamsi dan Kehamilan Normal serta Hubungannya dengan Berat Badan Lahir dan Tekanan Darah Ibu. Bagian Obstetri dan Ginecologi. FK.Unpad. 2010; 42 (1): 1-5.
42. Gao G. Dou P. G1 Phase-Dependent Expression of Bcl-2 mRNA and
Protein Correlates with Chemoresistance of Human Cancer Cells. The American Society for Pharmacology and Experimental Therapeutics. 2000; 58 (5): 1-10.
43. Strik H. Deininger M.et al. BCL-2 Family protein expression in initial
and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999; 67: 763-768.
44. Ikegaki N, Katsumata M,et al. Expression of bcl-2 in Small Cell Lung
Carcinoma Cells. American Association for cancer Research. February 2014; 54: 6-8.
60 45. Ribeiro M.D, Countinho L.M, The Role Of Apoptosis, Cell Proliferation
Index, BCL-2, and P53 in Glioblastoma Prognosis. Arq Neuropsiquiatr. 2004; 62 (2): 262-270
46. Hardian et al. Apoptosis Index, Expression p53, Bcl-2,and
Angiogenesis in Reccurence Endometrial Hyperplasia Patients. Undip
47. Marsden E Donald, Hacker F Neville. The Classification, Diagnosis and
Management of Endometrial Hyperplasia. Review in Gynaecological faktor yang mempengaruhi Practice 3 (2003)89-97
48. Goncharenko et al. Predictive Diagnosis of Endometrial Hyperplasia
and Personalized Therapeutic Strategy in Women of Fertile Age. The EPMA Journal. 2013: 14
49. Hannemann M, Alexander H, Cope N, Acheson N, Phillips A.
Endometrial Hyperplasia: a Clinical’s Review. Obstetrics, Gunaecology and Reproductive Medicine. 2014: 116-119
50. Allred D, Breast Center, Assestment of Prognostic and Predictive
Factors in Breast Cancer by Immunohistochemistry. Baylor College of Medicine. (2006): 4-5
Crosstabs
Kelompok Usia (thn) * Hiperplasia Endometrium non-atipik Crosstabulation
Hiperplasia Endometrium non-atipik
Total Simpleks Kompleks
Kelompok Usia (thn) <= 40 Count 10 5 15
% within Hiperplasia Endometrium non-atipik 45,5% 22,7% 34,1% > 40 Count 12 17 29 % within Hiperplasia Endometrium non-atipik 54,5% 77,3% 65,9% Total Count 22 22 44 % within Hiperplasia Endometrium non-atipik 100,0% 100,0% 100,0%
Bcl-2 observer 1 * Hiperplasia Endometrium non-atipik Crosstabulation
Hiperplasia Endometrium non-atipik
Total Simpleks Kompleks Bcl-2 observer 1 0 Count 6 6 12 % within Hiperplasia Endometrium non-atipik 27,3% 27,3% 27,3% 1 Count 10 4 14 % within Hiperplasia Endometrium non-atipik 45,5% 18,2% 31,8% 2 Count 1 7 8 % within Hiperplasia Endometrium non-atipik 4,5% 31,8% 18,2% 3 Count 5 5 10 % within Hiperplasia Endometrium non-atipik 22,7% 22,7% 22,7% Total Count 22 22 44 % within Hiperplasia Endometrium non-atipik 100,0% 100,0% 100,0%
Bcl-2 observer 2 * Hiperplasia Endometrium non-atipik Crosstabulation
Hiperplasia Endometrium non-atipik
Total Simpleks Kompleks Bcl-2 observer 2 0 Count 6 5 11 % within Hiperplasia Endometrium non-atipik 27,3% 22,7% 25,0% 1 Count 10 5 15 % within Hiperplasia Endometrium non-atipik 45,5% 22,7% 34,1% 2 Count 3 7 10 % within Hiperplasia Endometrium non-atipik 13,6% 31,8% 22,7% 3 Count 3 5 8 % within Hiperplasia Endometrium non-atipik 13,6% 22,7% 18,2% Total Count 22 22 44 % within Hiperplasia Endometrium non-atipik 100,0% 100,0% 100,0%
Explore
Hiperplasia Endometrium non-atipik
Descriptives
Hiperplasia Endometrium non-atipik Statistic Std. Error
Bcl-2 observer 1 Simpleks Mean 1,23 ,237
95% Confidence Interval for Mean Lower Bound ,74 Upper Bound 1,72 5% Trimmed Mean 1,20 Median 1,00 Variance 1,232 Std. Deviation 1,110 Minimum 0 Maximum 3 Range 3 Interquartile Range 2 Skewness ,656 ,491 Kurtosis -,832 ,953 Kompleks Mean 1,50 ,244
95% Confidence Interval for Mean Lower Bound ,99 Upper Bound 2,01 5% Trimmed Mean 1,50 Median 2,00 Variance 1,310 Std. Deviation 1,144 Minimum 0 Maximum 3 Range 3 Interquartile Range 2 Skewness -,105 ,491 Kurtosis -1,397 ,953
Bcl-2 observer 2 Simpleks Mean 1,14 ,211
95% Confidence Interval for Mean
Lower Bound ,70
Upper Bound 1,58
5% Trimmed Mean 1,10
Median 1,00
Variance ,981 Std. Deviation ,990 Minimum 0 Maximum 3 Range 3 Interquartile Range 2 Skewness ,675 ,491 Kurtosis -,325 ,953 Kompleks Mean 1,55 ,235
95% Confidence Interval for Mean Lower Bound 1,06 Upper Bound 2,03 5% Trimmed Mean 1,55 Median 2,00 Variance 1,212 Std. Deviation 1,101 Minimum 0 Maximum 3 Range 3 Interquartile Range 2 Skewness -,127 ,491 Kurtosis -1,253 ,953 Tests of Normality Hiperplasia Endometrium non-atipik Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Bcl-2 observer 1 Simpleks ,308 22 ,000 ,800 22 ,001
Kompleks ,214 22 ,010 ,855 22 ,004 Bcl-2 observer 2 Simpleks ,282 22 ,000 ,841 22 ,002
Kompleks ,206 22 ,016 ,870 22 ,008
Group Statistics
Subyek N Mean Std. Deviation Std. Error Mean
Skor_Intensitas2 dime nsion 1 1,00 22 1,1364 ,99021 ,21111 2,00 22 1,5455 1,10096 ,23473 NPar Tests Mann-Whitney Test Ranks Hiperplasia Endometrium
non-atipik N Mean Rank Sum of Ranks
Bcl-2 observer 1 Simpleks 22 21,00 462,00 Kompleks 22 24,00 528,00 Total 44 Bcl-2 observer 2 Simpleks 22 20,09 442,00 Kompleks 22 24,91 548,00 Total 44 Test Statisticsa Bcl-2 observer 1 Bcl-2 observer 2 Mann-Whitney U 209,000 189,000 Wilcoxon W 462,000 442,000 Z -,803 -1,292
Asymp. Sig. (2-tailed) ,422 ,196
a. Grouping Variable: Hiperplasia Endometrium non-atipik
Reliability
Scale: ALL VARIABLES Case Processing Summary
N %
Cases Valid 44 100,0
Excludeda 0 ,0 Total 44 100,0
a. Listwise deletion based on all variables in the procedure.
Symmetric Measures
Value
Asymp. Std.
Errora Approx. Tb Approx. Sig. Measure of Agreement Kappa ,908 ,051 10,355 ,000
N of Valid Cases 44
a. Not assuming the null hypothesis.
b. Using the asymptotic standard error assuming the null hypothesis.
Group Statistics
kelompok hiperplasia N Mean Std. Deviation
Std. Error Mean usia pasien simpleks 22 42.14 10.106 2.155
kompleks 22 43.18 7.974 1.700 skor Bcl 2 simpleks 22 2.68 2.476 .528
Tes normalitas data
One-Sample Kolmogorov-Smirnov Test
usia pasien skor Bcl 2
N 44 44
Normal Parameters(a,b) Mean 42.66 2.84 Std. Deviation 9.011 2.362 Most Extreme Differences Absolute .134 .185 Positive .094 .185 Negative -.134 -.115 Kolmogorov-Smirnov Z .889 1.224 Asymp. Sig. (2-tailed) .409 .100 a Test distribution is Normal.
b Calculated from data.
Independent Samples Test
Levene's Test for Equality of
Variances t-test for Equality of Means
F Sig. T df Sig. (2- tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference Upper Lower usia pasien Equal variances assumed .572 .454 -.381 42 .705 -1.045 2.744 -6.584 4.493 Equal variances not assumed -.381 39.845 .705 -1.045 2.744 -6.593 4.502 skor Bcl 2 Equal variances assumed .012 .914 -.443 42 .660 -.318 .719 -1.769 1.133 Equal variances not assumed -.443 41.742 .660 -.318 .719 -1.769 1.133
No Nama Usia Suku No. PA Subyek hiperplasia endometrium skor total Bcl-2 skor total Bcl-2
(thn) non atipik observer 1 observer 2
1 xxx 46 Batak B/1115/13 simpleks 1 1
2 xxx 50 Aceh B/1321/13 simpleks 2 2
3 xxx 36 Melayu B/3682/12 simpleks 0 0
4 xxx 43 Batak O/3538/14 simpleks 1 1
5 xxx 71 Batak B/2947/08 simpleks 3 2
6 xxx 43 Nias B/2643/09 simpleks 1 1
7 xxx 40 Jawa OK/112/14 simpleks 0 0
8 xxx 49 Melayu OK/103/14 simpleks 1 1
9 xxx 35 Batak OB/13/2014 simpleks 1 1
10 xxx 32 JAwa B/32/14 simpleks 0 0
11 xxx 30 Batak OK/31/14 simpleks 1 1
12 xxx 43 Batak B/283/13 simpleks 0 0
13 xxx 22 Batak B/266/13 simpleks 3 2
14 xxx 44 Aceh OK/233/13 simpleks 3 3
15 xxx 40 Jawa B/213/13 simpleks 1 1
16 xxx 40 Jawa B/208/13 simpleks 3 3
17 xxx 45 Melayu B/154/13 simpleks 1 1
18 xxx 40 Melayu OK/54/13 simpleks 0 0
19 xxx 28 Batak OK/357/12 simpleks 1 1
20 xxx 53 Batak OK/307/12 simpleks 1 1
21 xxx 46 Batak OK/270/12 simpleks 3 3
22 xxx 51 Batak HJ/257/14 simpleks 0 0
23 xxx 44 Jawa O/4462/13 kompleks 3 3
24 xxx 43 Aceh B/3134/13 kompleks 1 1
25 xxx 49 Jawa B/2294/12 kompleks 3 3
26 xxx 21 Melayu B/4858/09 kompleks 0 0